Tradewind has developed a multifaceted attack antibody for ovarian cancer. This antibody drug attacks primary and disseminated cancer cells directly. It also blocks the activity of immune cells called myeloid-derived suppressor cells (MDSCs). MDSCs potently suppress the activity of CD4+ and CD8+ T cells. Our antibody restores T cell anti-cancer immunity to enable and expand the utility of checkpoint inhibitors. It has been validated in vivo.